• USDA pegged U.S. hog slaughter at 9.56 million head in August 2013, 9.03 million head in September 2013 and 10.42 million head in October 2013. Rabobank's report comes out ahead the U.S. Department of Agriculture's quarterly hog and pig report on Friday that will give an update of how much PEDv has reduced the U.S. hog supply.

  • ZURICH, March 22- Results of two late-stage clinical trials showed high efficacy for Novartis' drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis, the Swiss drugmaker said on Saturday.

  • CAIRO/ LONDON, March 21- Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price.

  • March 21- Endocyte Inc's shares more than doubled after the company said its cancer drug was recommended for conditional approval in Europe for ovarian cancer and that the drug improved survival rates in lung cancer patients.

  • March 21- Endocyte Inc said its experimental drug improved survival rates in lung cancer patients without the disease worsening, when used in combination with an approved treatment.

  • Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide. It is expected to be approved in the United States later this year.

  • March 21- Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix. Hemophilia B, a rare inherited disorder in which the ability of a person's blood to clot is impaired, affects some 4,000 people in the United States and roughly 25,000 worldwide. It is expected to be approved in the United States later this year.

  • CARACAS, March 21- While hemophilia sufferer Sergio Tovar lay in agony for five days at a hospital in Venezuela, his friends and family scoured hospitals and pharmacies looking for life-saving drugs. Eventually a cousin, Jenny Sequeda, helped find a substitute for the protein coagulant Tovar needs for his blood condition.

  • *MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.

  • U.S. FDA approves Paladin drug to treat tropical disease Wednesday, 19 Mar 2014 | 6:40 PM ET

    Impavido, made by Canada's Paladin Labs Inc, is an oral medicine approved to treat the three main types of leishmaniasis: visceral, which affects internal organs; cutaneous, which affects the skin; and mucosal, which affects the nose and throat. This is the first drug approved by the FDA to treat cutaneous or mucosal leishmaniasis.

  • 'Eye-opening' new report about statin eligibility Wednesday, 19 Mar 2014 | 5:06 PM ET
    Lipitor tablets

    Almost half of Americans ages 40 to 75 qualify to consider cholesterol-lowering statin drugs under new heart disease prevention guidelines.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • March 18- Biogen Idec Inc said the U.S. Food and Drug Administration extended the review process for the company's multiple sclerosis drug by three months to evaluate the application. Biogen, which was expecting to launch the drug, Plegridy, by mid-2014, said the FDA did not ask for additional studies. Biogen shares closed at $345.60 on Monday on the Nasdaq.

  • Intercept shares drop on concerns about liver drug Monday, 17 Mar 2014 | 1:10 PM ET

    March 17- Shares of Intercept Pharmaceuticals Inc fell nearly 17 percent on Monday after the company said a trial showed patients taking its experimental liver disease drug experienced a higher number of heart-related problems than those given a placebo.

  • New data will be key to gauging hog market bubble Monday, 17 Mar 2014 | 11:29 AM ET

    Fund managers and traders have chased hog prices to record highs on fear of a deadly pig virus. But a market reversal could be possible.

  • March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.

  • Virginia has reported positive samples of the virus in the environment, but not yet in a hog herd, according to data released on Thursday by the U.S. Department of Agriculture's National Animal Health Laboratory Network.

  • ADHD big money for big pharma     Wednesday, 12 Mar 2014 | 2:49 PM ET

    CNBC's Sheila Dharmarajan reports 15 percent of high school aged children are diagnosed with ADHD, or attention deficit hyperactivity disorder.

  • Doctor concerned about ADHD misdiagnosis     Wednesday, 12 Mar 2014 | 2:48 PM ET

    Dr. Richard Saul wrote a book called "ADHD Does Not Exist." Saul is certain attention ADHD, or attention deficit hyperactivity disorder exists only in its symptoms. The condition does not exist.

  • Zogenix shares fall after Purdue advances rival drug Wednesday, 12 Mar 2014 | 9:37 AM ET

    March 12- Shares of Zogenix Inc fell 14 percent after Purdue Pharma LP said it was moving ahead with an abuse-resistant rival to Zogenix's much-criticised painkiller.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:40 AM ET

Loyalists around the world have embraced it as the cryptocurrency of the future, but some big names on the street differ widely in their beliefs about bitcoin. The Oracle of Omaha thinks it's a "joke." Tech entrepreneur Marc Andreessen counters that Buffett is out of touch, while bitcoin believers like Jonathan Rumion fully embrace the digital currency by buying groceries with bitcoin and even getting paid in bitcoin. CNBC's Mary Thompson reports.

Wednesday, 16 Apr 2014 | 3:00 AM ET

European shares opened higher on Wednesday as better-than-expected Chinese growth data buoyed sentiment.

Wednesday, 16 Apr 2014 | 2:00 AM ET

Brady Dougan, CEO of Credit Suisse, says the bank's fixed income business is "strong", while the investment banking arm has performed well.